CHM chimeric therapeutics limited

0.00%

0.4¢

will be interested to learn just how many patients were...

First 13 Last

Share
Profile

Follow
DrillDown2014

280 Posts.

66

11/01/24

08:23

Post #: 71823943
Share

Originally posted by pfeifer1982: ↑

Just noticed that the CHM 0201 Vactosertib trial is currently suspended (temporarily) due to insufficient staff (Christmas break?):

https://clinicaltrials.gov/study/NCT05400122?tab=table

Primary Completion Date however remains unchanged (Estimated): 1 June 2024.

Given the time Primary Outcome (1.) being 28 days after infusion, that would indicate dosing of the last patient to occur beginning of May (estimated).

Also worth noting that the trial seeks to enrol "up to 12 patients":
https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.4_suppl.TPS273

https://chimerictherapeutics.com/our-pipeline/#our-pipeline

This trial is not the same as the ADVENT-AML Phase 1B trial:
https://clinicaltrials.gov/study/NCT05834244

https://chimerictherapeutics.com/our-pipeline/#our-pipeline

Both trials are utilising the non-engineered allogeneic CORE-NK platform (CHM 0201), which is different to the autologous therapy CHM 1101 (CLTX), which recently dosed the last patient in a Phase 1A dose escalation study:
https://clinicaltrials.gov/study/NCT04214392

https://www.businessnews.com.au/article/Chimeric-moves-US-brain-cancer-trial-to-next-stage

Positive Preliminary Data was announced in October last year:

https://chimerictherapeutics.com/wp-content/uploads/2023/10/ASX-Announcement-23Oct2023-2627696.pdf

CLTX is currently tested in a Phase 1B trial:
https://clinicaltrials.gov/study/NCT05627323

https://chimerictherapeutics.com/our-pipeline/#clinical-trials

CHM 2101, an autologous CDH17 CAR T-cell therapy is due to start recruitment within the next 6 months in a Phase 1 dose escalation study, with Phase 2 dosing based on results from Phase 1:
https://classic.clinicaltrials.gov/ct2/show/NCT06055439

So much to see here...

Expand

will be interested to learn just how many patients were recruited as recruitment as fist dose was nearly 11 months prior to recruitment suspension.

would preliminary data be expected to be announced around the primary completion date or is the timing totally independent of this date? Not sure how closely you follow these trials but you seem to stay updated.

thanks for posting the trial links

CHM Price at posting: 3.4¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

SRL

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

OCC

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

ASX Market Open: IPO hype, Wall Street ATHs push Aussies into green hope | June 27

BOE

Boss extends June win streak with boosted Alta Mesa extraction rates

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

PAR

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

'Not possible' to port renewable gas: ACCC takes AGN to court

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

First 13 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 0.4¢		Change 0.000(0.00%)		Mkt cap ! $8.060M

Open	High	Low	Value	Volume
0.4¢	0.4¢	0.4¢	$19.57K	4.893M

Buyers (Bids)

No.	Vol.	Price($)
4	419507	0.4¢

Sellers (Offers)

Price($)	Vol.	No.
0.5¢	18587873	22

View Market Depth

No.	Vol.	Price($)
4	419507	0.004
40	26959271	0.003
16	15400505	0.002
12	54600000	0.001
0	0	0.000

Price($)	Vol.	No.
0.005	18587873	22
0.006	13384684	15
0.007	3100000	2
0.008	8542434	6
0.009	2390797	5

Last trade - 15.59pm 27/06/2025 (20 minute delay)

CHM (ASX) Chart

will be interested to learn just how many patients were...

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

ASX Market Open: IPO hype, Wall Street ATHs push Aussies into green hope | June 27

Boss extends June win streak with boosted Alta Mesa extraction rates

Australia’s gas crisis is here – and dying coal plants aren’t helping

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

'Not possible' to port renewable gas: ACCC takes AGN to court

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

will be interested to learn just how many patients were...

Top Stories

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

ASX Market Open: IPO hype, Wall Street ATHs push Aussies into green hope | June 27

Boss extends June win streak with boosted Alta Mesa extraction rates

Australia’s gas crisis is here – and dying coal plants aren’t helping

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

'Not possible' to port renewable gas: ACCC takes AGN to court

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News